---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-040981"
form_type: "8-K"
ticker: "APVO"
cik: "0001671584"
company_name: "Aptevo Therapeutics Inc."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T18:01:36.317152+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Aptevo Q2 net loss $7.9M; APVO436 DOR data positive; $5M raise extends cash into 3Q24

## Summary
- Net loss $7.9M ($1.23/share) vs net income $28.0M in Q2 2022 (which included $37.2M gain); cash $21.0M at June 30.
- Closed $5M public equity raise on Aug 4, 2023; warrants could add $10M; cash runway now into Q3 2024.
- APVO436 + venetoclax + azacitidine in AML: 82% (9/11) response rate for DOR analysis; 3 patients bridged to transplant.
- Phase 2 trials for APVO436 planned: relapsed/refractory in 2H23, frontline in 1H24; ALG.APV-527 Phase 1 interim data in 2H23.

## SEC filing metadata
- accession: 0000950170-23-040981
- form_type: 8-K
- ticker: APVO
- cik: 0001671584
- company_name: Aptevo Therapeutics Inc.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671584/000095017023040981/0000950170-23-040981-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671584/000095017023040981/apvo-20230810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-040981
- JSON: https://secwatch.observer/filing/0000950170-23-040981.json
- Plain text: https://secwatch.observer/filing/0000950170-23-040981.txt

## Key facts
- Earnings Releases
  Aptevo Therapeutics Inc. reported financial results for the quarter ended June 30, 2023.
  - Period: the quarter ended June 30, 2023
  - Result: reported results
  source text: On August 10, 2023, Aptevo Therapeutics Inc. (the “Company”) issued a press release announcing its financial results for the period ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1671584/000095017023040981/0000950170-23-040981-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.